Commentary: Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies

Commentary: Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies

Bibliographic Details
Main Authors:	Joseph R. Berger, Hans-Peter Hartung
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-03-01
Series:	Frontiers in Neurology
Subjects:	progressive multifocal leucoencephalopathy (PML) multiple sclerosis natalizumab risk factors immunogenetics
Online Access:	https://www.frontiersin.org/articles/10.3389/fneur.2023.1146027/full

Similar Items

Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies
by: Eli Hatchwell, et al.
Published: (2022-12-01)

Type O blood group associates with higher anti‐JC polyomavirus antibody levels
by: Pia Frenken, et al.
Published: (2021-08-01)

Is There a (Host) Genetic Predisposition to Progressive Multifocal Leukoencephalopathy?
by: Eli eHatchwell
Published: (2015-05-01)

Case Report: Findings Suggestive of Paraclinical Progressive Multifocal Leukoencephalopathy and Lung Cancer-Derived Brain Metastases in an MS Patient Treated With Fingolimod
by: Fabian Maass, et al.
Published: (2021-02-01)

Germline Genetic Risk Variants for Progressive Multifocal Leukoencephalopathy
by: Peggy S. Eis, et al.
Published: (2020-03-01)

Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy (PML).
by: Hans eLindå, et al.
Published: (2013-02-01)

Asymptomatic progressive multifocal leukoencephalopathy: a case report and review of the literature
by: Yinan Zhang, et al.
Published: (2018-07-01)

Progressive multifocal leukoencephalopathy as a complication of disease-modifying treatment of multiple sclerosis
by: Maria N. Zakharova, et al.
Published: (2018-12-01)

Insight into Metabolic 1H-MRS Changes in Natalizumab Induced Progressive Multifocal Leukoencephalopathy Brain Lesions
by: Ruth Schneider, et al.
Published: (2017-09-01)

Pembrolizumab for the treatment of Progressive Multifocal Leukoencephalopathy (PML) in a patient with AIDS: A case report and literature review
by: Tulika Chatterjee, et al.
Published: (2022-01-01)

Killing Two Birds With One Stone: Effective Control of Both Non-Small Cell Lung Cancer and Progressive Multifocal Leukoencephalopathy With Atezolizumab, A Case Report
by: Nicolas Lambert, et al.
Published: (2022-05-01)

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: risk reduction, management and possibilities for subsequent immunoregulation
by: Natalia V. Khachanova, et al.
Published: (2019-12-01)

Magnetic resonance imaging may simulate progressive multifocal leucoencephalopathy in a patient with chronic lymphocytic leukemia after fludarabine therapy
by: Kalita J, et al.
Published: (2008-01-01)

A case of progressive multifocal leukoencephalopathy in a HIV-infected female patient
by: E A Samotolkina, et al.
Published: (2016-11-01)

Smoldering myeloma presenting as progressive multifocal leukoencephalopathy: a case report
by: Troppmann Martina, et al.
Published: (2012-07-01)

Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study
by: Pilar Santiago-Setien, et al.
Published: (2023-02-01)

Human Polyomavirus JCPyV and Its Role in Progressive Multifocal Leukoencephalopathy and Oncogenesis
by: Luis Del Valle, et al.
Published: (2019-08-01)

Prevention and therapy of JC polyomavirus-mediated progressive multifocal leukoencephalopathy – a realistic possibility?
by: Ivan Jelcic, et al.
Published: (2017-10-01)

The importance of mouse models to define immunovirologic determinants of progressive multifocal leukoencephalopathy
by: Aron eLukacher, et al.
Published: (2015-01-01)

Effectiveness of Immune Checkpoint Inhibitors in Transplant Recipients with Progressive Multifocal Leukoencephalopathy
by: Chloé Medrano, et al.
Published: (2019-11-01)

Progressive Multifocal Leukoencephalopathy Diagnosed by Metagenomic Next-Generation Sequencing of Cerebrospinal Fluid in an HIV Patient
by: Huan Xia, et al.
Published: (2019-11-01)

A Chronic Lymphocytic Leukemia Patient with Progressive Multifocal Leukoencephalopathy Caused by John Cunningham Virus
by: Pristya Ramadhani, et al.
Published: (2018-06-01)

Progressive multifocal leukoencephalopathy restricted to the posterior fossa in a patient with systemic lupus erythematosus
by: Fabrício Guimarães Gonçalves, et al.

Not All Strokes Are Strokes - An Example of Diagnostic Confirmation Bias
by: Melanie Dani, et al.
Published: (2019-01-01)

Progressive multifocal leukoencephalopathy in a patient with multiple myeloma: a case report and analysis of the FDA adverse event reporting system
by: Elise Jonasson, et al.
Published: (2023-05-01)

Progressive Multifocal Leukoencephalopathy Associated to Multiple Sclerosis Therapies: Review of the literature
by: Ana-Maria Vladila, et al.
Published: (2015-12-01)

Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy
by: Viviana Lo Buono, et al.
Published: (2022-04-01)

Progressive multifocal leukoencephalopathy
by: Rosca Elena Cecilia, et al.
Published: (2008-12-01)

Severe Progressive Multifocal Leukoencephalopathy (PML) and Spontaneous Immune Reconstitution Inflammatory Syndrome (IRIS) in an Immunocompetent Patient
by: Lea Krey, et al.
Published: (2019-05-01)

Comparison of qPCR with ddPCR for the Quantification of JC Polyomavirus in CSF from Patients with Progressive Multifocal Leukoencephalopathy
by: Nyater Ngouth, et al.
Published: (2022-06-01)

Patient monitoring during treatment with natalizumab (ORP-24)
by: Zohreh Abna
Published: (2023-01-01)

Cerebrospinal fluid analysis in 108 patients with progressive multifocal leukoencephalopathy
by: Nora Möhn, et al.
Published: (2020-10-01)

Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab
by: Roberta Antonia Diotti, et al.
Published: (2016-05-01)

Serological profile of John Cunningham virus (JCV) in patients with multiple sclerosis
by: Luciana Prats Branco, et al.

Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment
by: Carla Prezioso, et al.
Published: (2021-08-01)

Alterations of the miR-126-3p/POU2AF1/Spi-B Axis and JCPyV Reactivation in Multiple Sclerosis Patients Receiving Natalizumab
by: Roberta Mancuso, et al.
Published: (2022-03-01)

A human T-lymphotropic virus-1 carrier who developed progressive multifocal leukoencephalopathy following immunotherapy for sarcoidosis: a case report
by: Takashi Nagahori, et al.
Published: (2023-02-01)

AIDS-related progressive multifocal leukoencephalopathy
by: Carolina de Oliveira Abrão, et al.
Published: (2020-12-01)

Immune Reconstitution Inflammatory Syndrome with Recurrent Paradoxical Cerebellar HIV-Associated Progressive Multifocal Leukoencephalopathy
by: Paola Frattaroli, et al.
Published: (2021-06-01)

Anxiety and Perception of Disease Control in Multiple Sclerosis Subjects Treated with Natalizumab
by: Francesco Corallo, et al.
Published: (2023-12-01)